
niabicyclo [2.2.2]octane; bromide
3(R)-(9-Hydroxy-9H-fluorene-9-carbonyloxy)-1-(3-thien-2-ylprop yl)-1-azoniabicyclo [2.2.2]octane; bromide
3(R)-(9-Methyl-9[H]-fluorene-9-carbonyloxy)-1-(3-phenylallyl)-1-azonia bicyclo [2.2.2]octane; bromide
3(R)-(9-Methyl-9[H]-fluorene-9-carbonyloxy)-1-(3-phenoxypropyl)-1-azo niabicyclo[2.2.2]octane; bromide
1-(4-Phenylbutyl)-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniab Icyclo [2.2.2]octane; bromide
1-(2-Phenoxyethyl)-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azonia Bicycle [2.2.2]octane; bromide
1-(3-Phenoxypropyl)-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoni Abicyclo [2.2.2]octane; bromide
1-Phenethyl-3(R)-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo [2.2.2] octane; bromide
3(R)-(9-Hydroxy-9[H]-xanthene-9-carbonyloxy)-1-(3-phenoxypropy l) -1-azoniabicyclo[2.2.2]octane; bromide
3(R)-(9-Hydroxy-9[H]-xanthene-9-carbonyloxy)-1-phenethyl-1-azo niabicy clo[2.2.2]octane; bromide
3(R)-(9-Hydroxy-9H-xanthene-9-carbonyloxy)-1-(3-thien-2-ylprop yl)-1-azoniabicyclo[2.2.2]octane; bromide or
3(R)-(9-Methyl-9[H]-xanthene-9-carbonyloxy)-1-(3-phenoxy-propy l)-1-azonia-bicyclo[2.2.2]octane; bromide


23. A compound according to any one of the preceding claims characterised in that it has an IC_{50} value for muscarinic M_3 receptors (Hm3) of less than 35 nM.

~~24. A process for the preparation of a compound of formula (I)~~




~~(I)~~

which comprises reacting an alkylating agent of formula (II)



(II)

with a compound of formula (III)




(III)

wherein, in each of formulae I, II and III, R^1, R^2, R^3, ©, A, X, B, n, m and p are as defined in any one of claims 1 to 22.

25. A process according to claim 24 characterised in that the resulting reaction mixture is purified by solid phase extraction.

26. A compound of formula (III)




(III)

wherein B and p are as defined in any one of claims 1, 4, 5, 14, 15 or 17 to 22 and wherein the substituent on the azabicyclo group has (R)- configuration.

27. A compound according to claim 26 which is
9-Methyl-9[H]-fluorene-9-carboxylic acid
1-azabicyclo[2.2.2]oct-3(R)-yl ester;
9-Methyl-9[H]-xanthene-9-carboxylic acid

~~1-azabicyclo[2.2.2]oct-3(R) -yl ester;~~
~~2-Hydroxy-2,2-difuran-2-yl-acetic acid~~
~~1-azabicyclo[2.2.2]oct-3(R) -yl ester.~~

~~28. A compound of formula (VII)~~



(VII)

~~(VII)~~

~~wherein p is defined in claim 1 or 5, R^8 is a 2-thienyl or 2-furyl group wherein the substituent on the azabicyclo group has (R) configuration.~~

~~29. A compound according to claim 28 which is~~
~~Oxothien-2-yl-acetic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester; or~~
~~Oxofuran-2-yl-acetic acid 1-azabicyclo[2.2.2]oct-3(R)-yl ester.~~

~~30. Use of a compound according to any one of claims 26 to 29 in a process for producing a compound of formula (I) as defined in any one of claims 1 to 22.~~

~~31~~24. A pharmaceutical composition comprising a compound according to any one of claims 1 to 23 in admixture with a pharmaceutically acceptable carrier or diluent.

~~32~~25. A compound according to any one of claims 1 to 23, or a pharmaceutical composition according to claim ~~31~~ 24 for use in a method of treatment of the human or animal body by therapy.

~~33~~26. Use of a compound according to any one of claims 1 to 23, or a pharmaceutical composition according to claim ~~31~~ 24 for the manufacture of a medicament for use in the treatment of respiratory, urinary or gastrointestinal disease.

~~34~~27. Use of a compound according to any one of claims 1 to 23 or a pharmaceutical composition according to claim ~~31~~ 24 for the manufacture of a medicament for use in the treatment of COPD, chronic bronchitis, asthma and rhinitis.